Lixte Biotechnology Holdings (FRA:8640) 3-Year EPS without NRI Growth Rate : 31.80% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings 3-Year EPS without NRI Growth Rate?

Lixte Biotechnology Holdings's EPS without NRI for the three months ended in Mar. 2025 was €0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 31.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Lixte Biotechnology Holdings was 31.80% per year. The lowest was -71.00% per year. And the median was -1.75% per year.

Competitive Comparison of Lixte Biotechnology Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Lixte Biotechnology Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's 3-Year EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Lixte Biotechnology Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Lixte Biotechnology Holdings (FRA:8640) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Lixte Biotechnology Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings Headlines

No Headlines